Amol Akhade

Amol Akhade highlights key trials on neoadjuvant chemotherapy in pancreatic cancer

Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared on X:

“Neoadjuvant chemo in Pancreatic Cancer: Which trial favors what?
We compared
  • PANACHE01 (just out in Journal of Clinical Oncology)
  • SWOG S1505
  • NORPACT-1
Only NORPACT-1 favored upfront surgery
Others showed feasibility and OS gain with NAC
Checkout both slides below.”

Amol Akhade

Title: Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study)

Journal: Journal of Clinical Oncology

Authors: Lilian Schwarz, Jean-Baptiste Bachet, Aurelia Meurisse, Olivier Bouché, Eric Assenat, Guillaume Piessen, Pascal Hammel, Nicolas Regenet, Julien Taieb, Olivier Turrini, Francois Paye, Anthony Turpin, Francois-Regis Souche, Christophe Laurent, Reza Kianmanesh, Pierre Michel, Dewi Vernerey, Jean-Yves Mabrut, Celia Turco, Stephanie Truant, Antonio Sa Cunha

Read the full article.

Amol Akhade

Learn more about Amol Akhade on OncoDaily. 

Amol Akhade Anthony Turpin Antonio Sa Cunha Aurelia Meurisse cancer Celia Turco Christophe Laurent Dewi Vernerey Eric Assenat Francois Paye Francois-Regis Souche Guillaume Piessen Jean-Baptiste Bachet Jean-Yves Mabrut Julien Taieb Lilian Schwarz neoadjuvant chemotherapy Nicolas Regenet NORPACT-1 Olivier Bouché Olivier Turrini OncoDaily Oncology PANACHE01 Pancreatic Cancer Pascal Hammel Pierre Michel Reza Kianmanesh Stephanie Truant Suyog Cancer Clinics SWOG S1505